BioMarin (BMRN) Q3 2026 Earnings Call Transcript

BioMarin’s Q3 2026 revenue rose 32% year over year to $1.025 billion, its first quarter above $1 billion, with metabolic-conditions revenue up 44% to $744 million. The company lowered full-year revenue guidance to $3.8 billion–$3.9 billion from $3.9 billion, citing a single international customer’s approximately $70 million in deferred orders and Middle East-related customer liquidity disruption; non-GAAP diluted EPS guidance is now $2.80–$3.10. Growth drivers include Amicus products and VOXZOGO, while acquisition and BMN-450 charges weigh on EPS; management expects $220 million in Amicus cost synergies to be fully realized by 2028 and says the deal is tracking to accretion in 2026.

Analysis

The key distinction is between patient demand and reported revenue: the near-term guide cut appears driven by customer/order timing, but the Middle East liquidity comments introduce a collection and repeat-order risk that could persist beyond a simple quarter shift. Treat BMRN’s Q4-to-Q1 recovery as unearned until orders ship and cash is collected. In the next 1–3 months, the most informative checks are Q4 order conversion, 2027 guidance, and evidence that Amicus cost savings are translating into operating leverage rather than being absorbed by integration and pipeline spend.

The more durable commercial read-through is mixed. Pompe starts helped by competitor supply disruption may create a larger treated base, but management cannot quantify how many patients stay after supply normalizes; do not capitalize the full reported patient growth as recurring. Conversely, if starts persist, delayed revenue recognition could make 2027 look stronger than current quarterly run-rates imply. VOXZOGO’s regulatory dates in 2027 offer catalysts, but competition and launch execution make the outcome less certain than the established portfolio. The Ascendis royalty settlement may partly offset BMRN’s exposure if Yuviwel takes share in an overlapping market; the net effect depends on product overlap, launch uptake, and royalty-eligible sales. It also gives ASND a potential revenue stream, not proof of material earnings contribution.

Contrarian angle: the headline growth rate overstates organic momentum because of the acquired business, while the order deferral may overstate demand weakness. Neither should drive a large position alone. Acquisition charges also make near-term EPS a poor read-through to underlying profitability; verify free cash flow, cash use, and the 2027 accretion bridge before underwriting the synergy story.

Key Decisions for Investors

• BMRN: consider a staged, modest long on broad-market weakness rather than chasing the earnings reaction. Reassess after Q4 results and 2027 guidance confirm order conversion and quantify Amicus accretion; the upside case is durable acquired-product growth plus synergy realization, while the main near-term downside is further order slippage or weaker cash conversion.
• Do not extrapolate Pompe’s supply-driven patient starts into a full-year run-rate. Track patient persistence and revenue conversion through 2027; reduce the thesis if starts reverse as competitors restore supply or management indicates the acquired patients are not retained.
• Treat the 2027 VOXZOGO regulatory decisions as event risk, not a base-case earnings contribution. Revisit exposure after the February achondroplasia decision and May hypochondroplasia decision; a delay, unfavorable label, or weak access preparation would falsify the launch-upside case.
• ASND: monitor Yuviwel launch and royalty disclosures before assigning value to the settlement. The missing inputs are eligible net sales, royalty timing, and the degree of overlap with BMRN’s products; absent those, no standalone ASND trade is warranted on this news.